Reduced folate status is common and increases disease risk. It can be corrected by daily ingestion of supplements or fortification

Novartis Foundation Symposium

Volumn 282, Issue , 2007, Pages 105-117

  Scott, John M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; VITAMIN B COMPLEX;

BLOOD; DIET SUPPLEMENTATION; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; NEURAL TUBE DEFECT; NUTRITIONAL REQUIREMENT; PHYSIOLOGY; PREGNANCY; REVIEW; RISK FACTOR; TIME;

DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; FOOD, FORTIFIED; HUMANS; NEURAL TUBE DEFECTS; NUTRITIONAL REQUIREMENTS; PREGNANCY; RISK FACTORS; TIME FACTORS; VITAMIN B COMPLEX;

EID: 35448945579     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (36)

1. Bønaa KH, Njølstad F, Ueland PM et al 2006 Homocysteine lowering and cardiovascular disease events after acute myocardial infarction. N Engl J Med 354:1-9
2. Botto LD, Lisi A, Robert-Gnansia E et al 2005 International retrospective cohort study of neural tube defects in relation to folic acid recommendations-are the recommendations working? BMJ 330:571
3. B-Vitamin Treatment Trialists Collaboration 2006 Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomised trials. Am Heart J 151:282-287
4. nd edn. Blackwell Science, Oxford
5. Clarke R, Grimley-Evans J, Schneede J et al 2004 Vitamin B-12 and folate deficiency in later life. Age Ageing 33:34-41
6. Cuskelly CJ, McNulty H, Scott JM 1996 Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet 347:657-659
7. Daly LE, Kirke PM, Molloy A, Weir DG, Scott JM 1995 Folate levels and neural tube defects. Implications for prevention. JAMA 274:1698-1702
8. Daly S, Molloy AM, Mills JL et al 1997 Minimum effective dose of folic acid for food fortification to prevent neural tube defects. Lancet 350:1666-1669
9. Department of Health 1992 Folic acid and the prevention of neural tube defects. Report from an expert advisory group. Department of Health, London
10. Hannon-Fletcher MP, Armstrong NC, Scott JM et al 2004 Determining bioavailability of food folates in a controlled intervention. Am J Clin Nutr 80:911-918
11. Homocysteine Studies Collaboration 2002 Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022
12. Honeim MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY 2001 Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981-2986
13. 12, biotin, and choline. Washington (District of Columbia): National Academy Press
14. Klerk M, Verhoef P, Clarke R et al 2002 MTHFR 677 C → T Polymorphism and risk of coronary heart disease. JAMA 288:2023-3030
15. Manzoor M, Runcie J 1976 Folate-responsive neuropathy: report of 10 cases. BMJ 1:1176-1178
16. McNulty H, McKinley MC, Wilson B et al 2002 Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 76:436-441
17. McNulty H, Dowey LR, Strain JJ et al 2006 Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677 C → T polymorphism. Circulation 113:74-80
18. McPartlin J, Scott JM 1997 Identification and assay of folate catabolites in human urine. Methods Enzymol 281:70-77
19. MRC Vitamin Study Research Group 1991 Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 338:131-137
20. Persad VL, Van den Hof MC, Dube JM, Zimmer P 2002 Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 167:241-245
21. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ 2005 Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey. Am J Clin Nutr 82:442-450
22. 12 in reduction of risk of vascular disease. Lancet 359:227-228
23. Ray JG, Meier C, Vermeulen MJ et al 2002 Association of neural tube defects and folic acid food fortification in Canada. Lancet 360:2047-2048
24. Scott JM 2001 Modification of hyperhomocystinuria. In: Carmel R, Jacobsen DW (eds) Homocysteine in Health and Disease, Cambridge University Press, UK p 467-476
25. 12 interrelationships. Essays Biochem 28:63-72
26. Scott JM, Weir DG 1998 Folic acid, Homocysteine and one carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk 5:223-227
27. Scott JM, Browne P 2006 ANAEMIA/Megaloblastic Anaemia. In: Sadler MJ, Caballero B, Strain JJ (eds) Encyclopaedia of Human Nutrition, Second Edition, Elsevier, p 109-117
28. Scott JM, Kirke PM, Weir DG 1990 The role of nutrition in neural tube defects. Annu Rev Nutr 10:277-295
29. Scott JM, Weir DG, Kirke P 1994 Folate and neural tube defects. In: Bailey LB (ed) Folate in health and disease. Marcel Dekker, New York p 329-360
30. Sweeney MR, McPartlin J, Weir DG, Daly L, Scott JM 2006 Postprandial serum folic acid response to multiple doses of folic acid in fortified bread. Br J Nutr 95:145-151
31. The Heart Outcomes Prevention Evaluation (HOPE) 2006 Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354-1-11
32. Toole JF, Malinow MR, Chambless LE et al 2006 Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575
33. Ulrich CM, Potter JD 2006 Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15:189-193
34. Wald DS, Law M, Morris JK 2002 Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 235:1-7
35. Weir DG, Scott JM 1995 The biochemical basis of the neuropathy in cobalamin deficiency. Baillieres Clin Haematol 8:479-497
36. Weir DH, Scott JM 1998 Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications. Nutr Res Rev 11:311-338